Table 1 Characteristics of patients at baseline and after LEF treatment
From: Leflunomide therapy for IgA vasculitis with nephritis in children
Patient # | Gender | Age | Body weight | Prior Mp therapy | Organ involvement | ISKDC grade | LEF treatment duration | Follow-up duration | Outcome |
|---|---|---|---|---|---|---|---|---|---|
1 | Female | 12 years | 55 kg | 1.45 mg/kg/day, 12 days 2.18 mg/kg/day, 7 days | S, A, K | II | 8 months | 12 months | No skin rash UP: 8 mg/kg/day |
2 | Male | 12 years | 45 kg | 1.78 mg/kg/day, 3 days 3.56 mg/kg/day, 8 days 11.11 mg/kg/day, 3 days | S, K | IIIb | 7 months | 8 months | No skin rash UP: undetectable |
3 | Female | 11 years | 35 kg | 2.29 mg/kg/day, 5 days 4.57 mg/kg/day, 6 days | S, K, J | IIIb | 12 months | 18 months | No skin rash UP: undetectable |
4 | Female | 11 years | 30 kg | 2.67 mg/kg/day, 6 days 5.33 mg/kg/day, 5 days 16.67 mg/kg/day, 3 days | S, K, J | IIIa | 6 months | 32 months | No skin rash UP: undetectable |
5 | Male | 12 years | 45 kg | 1.78 mg/kg/day, 4 days 3.56 mg/kg/day, 8 days | S, K | II | 6 months | 7 months | No skin rash UP: undetectable |